**Table S1. Change from baseline of allergic symptoms at 3 months.** TAAF: thickened amino acid-based formula; RAAF: reference amino acid-based formula; N: Number of subjects; SD: Standard deviation. \*Comparison of infants with symptom resolution vs infants with no symptom resolution; †Mac Nemar’s test; ‡Chi-2 test; §Fisher’s test; |symmetry test.

|  | **TAAF** | **RAAF** | **Total** |
| --- | --- | --- | --- |
| **Eczema, N (%)** |  |  |  |
| N | 25 | 27 | 52 |
| Worsening | 1 (4.0) | 3 (11.1) | 4 (7.7) |
| Unchanged | 7 (28.0) | 12 (44.4) | 19 (36.5) |
| Resolution | 17 (68.0) | 12 (44.4) | 29 (55.8) |
| P-value vs baseline | <0.001† | 0.020† | <0.001† |
| P-value between groups\* |  |  | 0.087‡  |
| **Skin dryness, N (%)** |  |  |  |
| N | 24 | 26 | 50 |
| Worsening | 2 (8.3) | 2 (7.7) | 4 (8.0) |
| Unchanged | 4 (16.7) | 13 (50.0) | 17 (34.0) |
| Resolution | 18 (75.0) | 11 (42.3) | 29 (58.0) |
| P-value vs baseline | <0.001† | 0.013† | <0.001† |
| P-value between groups\* |  |  | 0.019‡ |
| **Wheezing, N (%)** |  |  |  |
| N | 22 | 8 | 30 |
| Worsening | 6 (27.3) | 3 (37.5) | 9 (30.0) |
| Unchanged | 1 (4.5) | 1 (12.5) | 2 (6.7) |
| Resolution | 15 (68.2) | 4 (50.0) | 19 (63.3) |
| P-value vs baseline | 0.049† | 0.705† | 0.059† |
| P-value between groups\* |  |  | 0.545§ |
| **Rhinitis, N (%)** |  |  |  |
| N | 30 | 19 | 49 |
| Worsening | 4 (13.3) | 7 (36.8) | 11 (22.4) |
| Unchanged | 11 (36.7) | 2 (10.5) | 13 (26.5) |
| Resolution | 15 (50.0) | 10 (52.6) | 25 (51.0) |
| P-value vs baseline | 0.012† | 0.467† | 0.020† |
| P-value between groups\* |  |  | 0.858‡ |
| **Vomiting, N (%)** |  |  |  |
| N | 16 | 16 | 32 |
| Worsening | 2 (12.5) | 0 | 2 (6.3) |
| Unchanged | 0 (0.0) | 2 (12.5) | 2 (6.3) |
| Improved | 0 (0.0) | 3 (18.8) | 3 (9.4) |
| Resolution | 14 (87.5) | 11 (68.8) | 25 (78.1) |
| P-value vs baseline | 0.150| | 0.030| | 0.001| |
| P-value between groups\* |  |  | 0.394§ |
| **Regurgitations, N (%)** |  |  |  |
| N | 27 | 25 | 52 |
| Worsening | 0 (0.0) | 1 (4.0) | 1 (1.9) |
| Unchanged | 4 (14.8) | 5 (20.0) | 9 (17.3) |
| Improved | 5 (18.5) | 8 (32.0) | 13 (25.0) |
| Resolution | 18 (66.7) | 11 (44.0) | 29 (55.8) |
| P-value vs baseline | 0.344| | 0.650| | 0.007| |
| P-value between groups\* |  |  | 0.100‡ |